title: Plasma osteopontin levels and expression in adipose tissue are increased in obesity.
abstract: BACKGROUND
  Obesity acts as a cardiovascular risk factor by mechanisms that are not fully understood. Osteopontin (OPN) is a proinflammatory mediator involved in tissue remodeling that plays a role in atherosclerosis and diabetes.
  
  
  OBJECTIVE
  The aim of the present study was to compare the circulating concentrations of OPN and its mRNA expression in omental adipose tissue of lean, overweight, and obese individuals and to analyze the effect of weight loss.
  
  
  METHODS
  Plasma concentrations of OPN were measured in 77 volunteers. OPN mRNA expression in omental adipose tissue obtained from 12 women was quantified by real-time PCR. In addition, the concentrations of OPN in 12 obese men were measured before and after weight loss following a dietetic program.
  
  
  METHODS
  The study was conducted at a University Hospital.
  
  
  RESULTS
  Obese and overweight patients exhibited significantly increased circulating OPN concentrations as compared with lean subjects (obese 72.6 +/- 28.5, overweight 68.2 +/- 20.8, lean 42.7 +/- 27.9 ng/ml; P < 0.001). A significant positive correlation was found between OPN levels and body fat (r = 0.45; P < 0.0001). Obese individuals showed significantly increased (P < 0.05) mRNA expression of OPN in omental adipose tissue as compared with lean volunteers, which was further increased in obese diabetic patients. Diet-induced weight loss significantly decreased OPN concentrations from 64.7 +/- 22.1 to 36.6 +/- 20.1 ng/ml (P = 0.006).
  
  
  CONCLUSIONS
  These findings represent the first observation that plasma OPN and mRNA expression of OPN in omental adipose tissue are increased in overweight/obese patients with the latter being further elevated in obesity-associated diabetes. Moreover, weight loss reduces OPN concentrations, which may contribute to the beneficial effects accompanying weight reduction. Measurement of OPN might be useful for evaluating the outcomes of various clinical interventions for obesity-related cardiovascular diseases.
authors.affiliation: Metabolic Research Laboratory, Clínica Universitaria de Navarra, University of Navarra, 31008 Pamplona, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Gómez-Ambrosi
authors.forename: Victoria
authors.initials: V
authors.lastname: Catalán
authors.forename: Beatriz
authors.initials: B
authors.lastname: Ramírez
authors.forename: Amaia
authors.initials: A
authors.lastname: Rodríguez
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Colina
authors.forename: Camilo
authors.initials: C
authors.lastname: Silva
authors.forename: Fernando
authors.initials: F
authors.lastname: Rotellar
authors.forename: Carmen
authors.initials: C
authors.lastname: Mugueta
authors.forename: María J
authors.initials: MJ
authors.lastname: Gil
authors.forename: Javier A
authors.initials: JA
authors.lastname: Cienfuegos
authors.forename: Javier
authors.initials: J
authors.lastname: Salvador
authors.forename: Gema
authors.initials: G
authors.lastname: Frühbeck
mesh_terms: D000328:Adult; D015992:Body Mass Index; D004038:Diet, Reducing; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D050152:Intra-Abdominal Fat / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000178:diet therapy / Q000235:genetics*; D009852:Omentum / Q000378:metabolism; D053495:Osteopontin / Q000097:blood* / Q000235:genetics*; D012333:RNA, Messenger / Q000378:metabolism; D015431:Weight Loss
chemical_list: D012333:RNA, Messenger; D053495:Osteopontin